Works matching IS 01145916 AND DT 2022 AND VI 45 AND IP 1


Results: 8
    1
    2
    3
    4
    5
    6
    7

    RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.

    Published in:
    Drug Safety, 2022, v. 45, n. 1, p. 45, doi. 10.1007/s40264-021-01127-2
    By:
    • Nadal, Ernest;
    • Horinouchi, Hidehito;
    • Shih, Jin-Yuan;
    • Nakagawa, Kazuhiko;
    • Reck, Martin;
    • Garon, Edward B.;
    • Wei, Yu-Feng;
    • Kollmeier, Jens;
    • Frimodt-Moller, Bente;
    • Barrett, Emily;
    • Lipkovich, Olga;
    • Visseren-Grul, Carla;
    • Novello, Silvia
    Publication type:
    Article
    8

    A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007–2019).

    Published in:
    Drug Safety, 2022, v. 45, n. 1, p. 37, doi. 10.1007/s40264-021-01124-5
    By:
    • Perri-Plandé, Joelle;
    • Miremont-Salamé, Ghada;
    • Micallef, Joëlle;
    • Herman, Cameron;
    • Baumevieille, Marie;
    • Abriat, Frédéric;
    • Lapeyre-Mestre, Maryse;
    • Haramburu, Françoise;
    • Daveluy, Amélie;
    • The French Addictovigilance Network;
    • Fouilhé, Nathalie;
    • Boucher, Alexandra;
    • Pain, Stéphanie;
    • Djezzar, Samira;
    • Peyrière, Hélène;
    • Gérardin, Marie;
    • Fournier-Choma, Christine;
    • Gibaja, Valérie;
    • Boisselier, Reynald;
    • Caous, Anne-Sylvie
    Publication type:
    Article